178 related articles for article (PubMed ID: 26471970)
1. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract][Full Text] [Related]
2. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2011 Feb; 96(2):E288-96. PubMed ID: 21147882
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
4. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Corrado A; Fioravanti A; Sartini S; Orlandi P; Piaggi S; Corti A; Materazzi G; Galleri D; Ulisse S; Fontanini G; Danesi R; Da Settimo F; Miccoli P
Mol Cell Endocrinol; 2014 Aug; 393(1-2):56-64. PubMed ID: 24931161
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
6. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
[TBL] [Abstract][Full Text] [Related]
8. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
Carlomagno F; Vitagliano D; Guida T; Basolo F; Castellone MD; Melillo RM; Fusco A; Santoro M
J Clin Endocrinol Metab; 2003 Apr; 88(4):1897-902. PubMed ID: 12679489
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
12. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
[TBL] [Abstract][Full Text] [Related]
13. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
Bocci G; Fioravanti A; La Motta C; Orlandi P; Canu B; Di Desidero T; Mugnaini L; Sartini S; Cosconati S; Frati R; Antonelli A; Berti P; Miccoli P; Da Settimo F; Danesi R
Biochem Pharmacol; 2011 Jun; 81(11):1309-16. PubMed ID: 21459081
[TBL] [Abstract][Full Text] [Related]
15. N- and s-substituted Pyrazolopyrimidines: A promising new class of potent c-Src kinase inhibitors with prominent antitumor activity.
Awaji AA; Zaloa WAZE; Seleem MA; Alswah M; Elsebaei MM; Bayoumi AH; El-Morsy AM; Alfaifi MY; Shati AA; Elbehairi SEI; Almaghrabi M; Aljohani AKB; Ahmed HEA
Bioorg Chem; 2024 Apr; 145():107228. PubMed ID: 38422592
[TBL] [Abstract][Full Text] [Related]
16. Eco-friendly Synthesis of Pyrido[2,3-d]pyrimidine Analogs and Their Anticancer and Tyrosine Kinase Inhibition Activities.
El-Naggar AM; Khalil AK; Zeidan HM; El-Sayed WM
Anticancer Agents Med Chem; 2017; 17(12):1644-1651. PubMed ID: 28403776
[TBL] [Abstract][Full Text] [Related]
17. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
[TBL] [Abstract][Full Text] [Related]
18. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Pan J; Hao Q; Li Y; Zhou W
Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
[TBL] [Abstract][Full Text] [Related]
20. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
